Abstract
The Clinical Stage Partnering Agreements in Biopharma report provides
comprehensive understanding and unprecedented access to the clinical stage
agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why
companies enter clinical stage partnering deals.
Understanding the flexibility of a prospective partner' s negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases and databases do not.
This report contains over 1000 links to online copies of actual clinical stage
contract documents as submitted to the Securities Exchange Commission by
biopharma companies and their partners. Contract documents provide the answers
to numerous questions about a prospective partner' s flexibility on a wide
range of important issues, many of which will have a significant impact on
each party' s ability to derive value from the deal.
The initial chapters of this report provide an orientation of clinical stage
dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 provides an analysis of the trends in clinical stage
partnering as well as a discussion on the merits and attributes of dealmaking
at each stage of clinical development.
Chapter 3 provides an overview of the structure of clinical stage partnering
deal contracts. The chapter includes numerous case studies to enable
understanding of both pure deals and multicomponent clinical stage partnering
deals.
Chapters 4, 5 and 6 provide a review of the leading phase I, II and III
clinical stage partnering deals since 2000, respectively. Deals are listed by
headline value, signed by bigpharma, most active bigpharma, and most active of
all biopharma companies. Where the deal has an agreement contract published at
the SEC a link provides online access to the contract.
Chapter 7 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of clinical stage
contract documents available in the public domain. Each deal title links via
Weblink to an online version of the actual contract document, providing easy
access to each contract document on demand.
Chapters 8, 9 and 10 provide a comprehensive listing of all phase I, II and
III clinical stage agreement contracts since 2003 available in the public
domain, respectively. Each chapter is organized by A-Z, therapeutic area, and
deal type. Each deal title links via Weblink to an online version of the
actual contract document, providing easy access to each contract document on
demand. The report also includes numerous tables and figures that illustrate
the trends and activities in clinical stage dealmaking since 2000.
In conclusion, this report provides everything a prospective dealmaker needs
to know about clinical stage partnering, enabling thorough learning, education
and due diligence prior and during the clinical stage dealmaking process.
| 
View Cart
